Tus kws kho mob
QP79-24 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective January 1, 2025
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 13, 2024
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 511 - 520 ntawm 3669
Tus kws kho mob
QP81-24 Health Equity Certification 2025 Launch
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 13, 2024
Tus kws kho mob
QP78-24 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective December 1, 2024
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 13, 2024
Tus kws kho mob
QP84-24 Commercial Pharmacy Benefit Exclusion for Tremfya® and Ocrevus Zunovo™
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 13, 2024
Tus kws kho mob
P75-24 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans Managed by Blue Cross and Blue Shield of Alabama
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 02, 2024
Tus kws kho mob
Upcoming Policies Effective February 3, 2025
Tus kws kho mob
Vasomotor Symptoms (formerly Neurokinin Receptor Antagonists) - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ob Hlis Ntuj Tim 01, 2024
Tus kws kho mob
QP83-24 MHCP Pharmacy Benefit Exclusion for Tremfya®, Tecentriq Hybreza™ and Ocrevus Zunovo™
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 13, 2024
Tus kws kho mob
QP82-24 Enhanced Authorization Submissions through Availity Essentials
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 13, 2024
Tus kws kho mob
QP80-24 Commercial Pharmacy Benefit Exclusion for Select Medications
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 13, 2024